TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02509507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10\^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 \& 2, up to 8mL in Cohorts 3 \& 4 of the Group A \& Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10\^6 PFU/mL to the 2nd dose at 10\^7 or 10\^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 \& 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10\^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10\^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 \[dated 26 October 2021\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10\^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 \& 2, up to 8mL in Cohorts 3 \& 4 of the Group A \& Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10\^6 PFU/mL to the 2nd dose at 10\^7 or 10\^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 \& 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10\^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10\^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 \[dated 26 October 2021\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
Study: NCT04062461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted strategy based on sending text messages(SMS)
Description: multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol.
Study: NCT02509507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
Study: NCT00806403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reteplase 10+10 U
Description: comparison to primary PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary PCI
Description: comparison to thrombolysis
Study: NCT04689191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group A and C meningococcal polysaccharide vaccine
Description: One dose of Experimental Group A and C meningococcal polysaccharide vaccine
Study: NCT02320604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of study drug
Description: i.v. administration of Ambisome in two different dossages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of study drug
Description: i.v. administration of Ambisome in two different dossages
Study: NCT05487508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of intraoperative 1 mg/kg body weight dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of intraoperative 1 mg/kg body weight dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo (NaCl 0.9%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo (NaCl 0.9%)
Study: NCT01360151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab(Lucentis), verteporfin(Visudyne)
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab(Lucentis), verteporfin(Visudyne)
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ranibizumab(Lucentis), verteporfin(Visudyne)
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
Study: NCT04325659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge Device
Description: An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
Study: NCT04062461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual outpatient care
Description: Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
Study: NCT01690520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo high dose or middle intensity TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo high dose or middle intensity TBI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
Study: NCT01802840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: biscuits supplemented with soy fiber
Description: Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: biscuits supplemented with soy fiber
Description: Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
Study: NCT03101579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
Study: NCT04667273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Description: Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise Training (ET)
Description: Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband.
Study: NCT03639961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated leading, managing and governing for results model
Description: Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model
Description: Traditional model is a health service delivery model already in place in the government health system.
Study: NCT01165242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®
Description: One intramuscular injection
Study: NCT02360397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranolazine
Description: Ranolazine 1000 mg tablet twice daily for 30 days
Study: NCT02751060

Intervention type: OTHER
Intervention: No intervention
Study: NCT04311138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community-based reablement service
Description: Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multicomponent training
Description: control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
Study: NCT01204060

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal allergen challenge
Description: Subjects will receive a nasal spray containing an allergen to which they are allergic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal placebo challenge
Description: Subjects will receive a nasal spray with allergen diluent
Study: NCT01894113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transbronchial lung biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transbronchial lung biopsy
Study: NCT01653470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024
Study: NCT03580759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREHAB
Description: After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
Study: NCT01361906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensomotoric training
Description: The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today.
Study: NCT02431481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg
Study: NCT02885935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended protein intake
Description: Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated protein intake
Description: Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
Study: NCT01456702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: risk stratification group
Description: goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
Study: NCT02104128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
Study: NCT02082912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill PO twice weekly (Monday and Wednesday) for three weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandMentor Pro
Description: The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HandMentor Pro
Description: The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
Study: NCT04365283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New Bioactive Restorative Material (ACTIVA Presto)
Description: New Bioactive Restorative Material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)
Description: High Viscosity Glass Hybrid Reinforced Glass Ionomer
Study: NCT02177747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy conducted using a smartphone equipped with a compact addon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study: NCT00833547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg of eszopiclone at bedtime on two consecutive nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Study: NCT04719247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
Study: NCT04325659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
Study: NCT04689191

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group A and C meningococcal polysaccharide vaccine
Description: One dose of Control Group A and C meningococcal polysaccharide vaccine
Study: NCT01017874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: 250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
Study: NCT04714424

Intervention type: DEVICE
Intervention: Virtual Reality Headset
Description: Virtual reality (VR) - a 3-D reality right in a headset